153. Ann Oncol. 2018 May 1;29(5):1329-1330. doi: 10.1093/annonc/mdy067.Should de-escalation of bone-targeting agents be standard of care for patientswith bone metastases from breast cancer? A systematic review and meta-analysis.Liu C(1), Wang L(1), Zhuang J(2), Liu L(2), Zhou C(2), Feng F(2), Sun C(3).Author information: (1)College of Traditional Chinese Medicine, Shandong University of TraditionalChinese Medicine, Jinan.(2)Department of Oncology, Weifang Traditional Chinese Hospital, Weifang.(3)Department of Oncology, Affiliated Hospital of Weifang Medical University,Weifang, China.DOI: 10.1093/annonc/mdy067 PMID: 29788163 